Niagen Bioscience, Inc. (NAGE) Financial Statements
Industry: Medicinal Chemicals & Botanical Products
In fiscal 2025, Niagen Bioscience reported revenue of $129.4M, up 29.9% from $99.6M the year before. Net income was $17.4M (a 13.4% net margin), or $0.20 per diluted share. Gross margin was 64.3% and operating margin was 12.6%. Operating activities generated $13.5M of cash. At fiscal year end, Niagen Bioscience held $106.4M in total assets against $29.9M in total liabilities.
Open the full interactive Niagen Bioscience financials → Quarterly statements, key ratios, valuation history and price charts.
Niagen Bioscience Key Stats
| Share Price | $2.58 |
|---|---|
| Market Cap | $212.9M |
| P/E Ratio | 12.9 |
| Revenue YoY Growth | +29.9% |
| 52-Week Range | $2.58 – $7.60 |
| Shares Outstanding | 79.3 million (basic, 2026 Q2) |
Niagen Bioscience Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $59.3M | $67.4M | $72.0M | $83.6M | $99.6M | $129.4M |
| Gross Profit | $35.3M | $41.5M | $42.8M | $50.8M | $61.6M | $83.2M |
| Operating Income | -$19.9M | -$27.1M | -$18.6M | -$5.6M | $7.7M | $16.3M |
| Pre-Tax Income | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.9M | $18.2M |
| Income Tax | — | — | — | — | $305,000 | $810,000 |
| Net Income | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.6M | $17.4M |
| Diluted EPS | -$0.33 | -$0.40 | -$0.24 | -$0.07 | $0.11 | $0.20 |
Niagen Bioscience Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $34.0M | $33.8M | $31.5M | $29.8M |
| Net Income | $4.6M | $4.1M | $6.3M | $963,000 |
| Diluted EPS | $0.05 | $0.05 | $0.07 | $0.01 |
Niagen Bioscience Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.7M | $28.2M | $20.3M | $27.2M | $44.5M | — |
| Current Assets | $32.2M | $48.9M | $46.6M | $49.5M | $64.1M | $96.8M |
| Total Assets | $38.4M | $57.8M | $54.1M | $55.0M | $68.3M | $106.4M |
| Current Liabilities | $16.5M | $17.6M | $17.9M | $20.6M | $17.9M | $19.9M |
| Total Long-Term Debt | $3.6M | — | — | — | — | — |
| Total Liabilities | $21.9M | $26.1M | $25.4M | $26.5M | $22.2M | $29.9M |
| Shareholders' Equity | $16.4M | $31.7M | $28.7M | $28.5M | $46.1M | $76.5M |
Niagen Bioscience Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.6M | -$24.2M | -$15.1M | $7.1M | $12.1M | $13.5M |
| Cash From Investing | -$165,000 | -$409,000 | -$334,000 | -$143,000 | -$143,000 | -$292,000 |
| Cash From Financing | $8.7M | $36.1M | $7.7M | -$90,000 | $5.4M | $6.9M |
| Free Cash Flow | — | — | -$15.1M | $7.1M | $12.1M | — |
Figures from Niagen Bioscience's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Niagen Bioscience financials page for every line item.
Niagen Bioscience Company Profile
| Ticker | NAGE |
|---|---|
| Exchange | Nasdaq |
| Industry | Medicinal Chemicals & Botanical Products |
| Headquarters | Los Angeles, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001386570 |
Frequently Asked Questions
What was Niagen Bioscience's revenue in fiscal 2025?
Niagen Bioscience (NAGE) reported revenue of $129.4M for fiscal 2025.
What is Niagen Bioscience's annual revenue history?
Niagen Bioscience's annual revenue by fiscal year: 2020: $59.3M; 2021: $67.4M; 2022: $72.0M; 2023: $83.6M; 2024: $99.6M; 2025: $129.4M.
What was Niagen Bioscience's net income in fiscal 2025?
Niagen Bioscience reported net income of $17.4M for fiscal 2025.
What was Niagen Bioscience's earnings per share (EPS) in fiscal 2025?
Niagen Bioscience's diluted EPS was $0.20 for fiscal 2025 (adjusted for any later stock splits).
What was Niagen Bioscience's revenue last quarter?
In its most recent reported quarter (2026 Q2), Niagen Bioscience reported revenue of $29.8M.
How many shares of Niagen Bioscience are outstanding?
Niagen Bioscience reported a weighted average of 79.3 million basic shares outstanding in 2026 Q2.
What is Niagen Bioscience's market cap?
Based on its latest closing price, Niagen Bioscience (NAGE) has a market capitalization of about $212.9M.
When does Niagen Bioscience's fiscal year end?
Niagen Bioscience's fiscal year end, as registered with the SEC, is December 31.
Where is Niagen Bioscience headquartered?
Niagen Bioscience lists its business address in Los Angeles, California in its SEC filings.